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To the Editor

 {#hon2637-sec-0001}

Extranodal natural killer/T‐cell lymphoma, nasal type (ENKL) is an invasive non‐Hodgkin\'s lymphoma originating from mature NK cells or NK‐like T cells.[1](#hon2637-bib-0001){ref-type="ref"} The clinical manifestation of ENKL is atypical and highly variable, depending on the location of the disease and its histology. Various clinics are exploring the efficacies of different regimens such as radiotherapy,[2](#hon2637-bib-0002){ref-type="ref"} chemotherapy,[3](#hon2637-bib-0003){ref-type="ref"} chemoradiotherapy,[4](#hon2637-bib-0004){ref-type="ref"} autologous hematopoietic stem cell transplantation (AHSCT),[5](#hon2637-bib-0005){ref-type="ref"} allo‐HSCT,[6](#hon2637-bib-0006){ref-type="ref"} and other new drugs, but no optimal regimen has yet been reported for ENKL treatment. This study retrospectively analyzed and summarized the clinical data of 269 cases of ENKL treated in our hospital from 2007 to 2017. The goal of the study was to compare the effects of various treatment regimens on the survival of patients and gather evidence and experience in the individualized clinical treatment of ENKL.

Patients were evaluated weekly during treatment and followed up after treatment according to the institutional policy.[7](#hon2637-bib-0007){ref-type="ref"} Clinical examinations, imaging assessments, and pathological examinations were employed to evaluate the treatment response at every cycle and one month after the end of treatment according to the adapted Cheson\'s standard criteria.[8](#hon2637-bib-0008){ref-type="ref"} While complete response (CR) was defined as no evidence of residual disease, partial response (PR) was defined as a reduction of at least 50% of the pretreatment tumor burden. Stable disease (SD) was defined as less than 50% residual tumor burden or no disease progression, while progressive disease (PD) was characterized by an increase of greater than or equal to 20% in the maximal diameter of the tumor burden or appearance of new lesions. The overall response rate (ORR) was calculated as CR + PR. Treatment‐related toxicity was evaluated based on the National Cancer Institute\'s Common Toxicity Criteria (version 3).[9](#hon2637-bib-0009){ref-type="ref"} Progression‐free survival (PFS) was calculated from the date of diagnosis to the date of identification of disease progression and was censored at the date of the last follow‐up visit. Overall survival (OS) was calculated from the date of diagnosis to the date of death from any cause and was censored at the date of the last follow‐up visit. OS and PFS rates were analyzed using the Kaplan--Meier method.

As a result, a total of 269 patients (175 men and 94 women) fit the diagnostic criteria[10](#hon2637-bib-0010){ref-type="ref"} for ENKL. The median age of the patients was 44 years (range: 10--78). However, 27.1% of the patients were under the age of 30, indicating a decrease in the age of onset of ENKL. Most cases were positive for cytoplasmic CD3 (89.5%), CD56 (85.1%), T cell‐restricted intracellular antigen 1 (81.0%), and granzyme B (78.1%), which were indicative of tumor cells originating from NK cells. While 72.1% of the cases were positive for the Epstein--Barr encoding region in situ hybridization (EBER‐ISH), 93.5% of them were positive for plasma Ki‐67, which was suggestive of highly malignant cells.

In stage I/II disease (Table [1](#hon2637-tbl-0001){ref-type="table"}), the CR rate and ORR were 89.7% and 93.1%, respectively, in patients receiving the DDGP + IMRT treatment (n = 29); 33.3% and 50.0%, respectively, in patients receiving the SMILE treatment (n = 6); 66.7% and 73.3%, respectively, in patients receiving the VIPD treatment (n = 15); 84.2% and 89.4%, respectively, in patients receiving the VIPD + IMRT treatment (n = 19); and 11.1% and 22.2%, respectively, in patients receiving the AHSCT treatment (n = 9). In stage III/IV disease, the CR rate and ORR in patients receiving the DDGP + IMRT treatment (n = 13) were 76.9% and 84.6%, respectively; while in patients receiving the SMILE treatment (n = 18), they were 77.8% and 88.9%, respectively; in patients receiving the VIPD treatment (n = 5), they were 20.0% and 40.0%, respectively; and in patients receiving the AHSCT treatment (n = 9) were 70.0% and 80.0%, respectively.

###### 

Treatment modalities and responses of extranodal natural killer/T‐cell lymphoma, nasal type (ENKL) patients

                 Regimens   Number of Patients   CR   PR   SD   PD     ORR (%)
  -------------- ---------- -------------------- ---- ---- ---- ------ ---------
  Stage I/II     IMRT       11                   5    0    6    0      45.5
  DDGP           57         47                   4    2    4    89.5   
  DDGP+IMRT      29         26                   1    0    2    93.1   
  SMILE          6          2                    1    2    1    50.0   
  VIPD           15         10                   1    1    3    73.3   
  VIPD+IMRT      19         16                   1    1    1    89.4   
  AHSCT          9          1                    1    3    4    22.2   
  Stage III/IV   DDGP       72                   52   7    0    13     81.9
  DDGP+IMRT      13         10                   1    0    2    84.6   
  SMILE          18         14                   2    1    1    88.9   
  VIPD           5          1                    1    2    1    40.0   
  AHSCT          10         7                    1    1    1    80.0   

Abbreviations: AHSCT, autologous hematopoietic stem cell transplantation; CR, complete response; DDGP, dexamethasone/cisplatin/gemcitabline/pegaspargase; IMRT, intensity modulated radiation therapy; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; SMILE, dexamethasone/methotrexate/ifosfamide/L‐asparaginase/etoposide; VIPD, etoposide/ifosfamide/cisplatin/dexamethasone.

In addition, for the whole cohort, the CR/ORR were 85.7%/90.5% in patients receiving the DDGP + IMRT treatment, 76.7%/85.3% in patients receiving the DDGP treatment, 66.7%/79.2% in patients receiving the SMILE treatment, 55.0%/65.0% in patients receiving the VIPD treatment, and 42.1%/52.6% in patients receiving the AHSCT treatment.

At a median follow‐up of 56 months (range: 1--120), five patients had died; three of hemophagocytic syndrome (HPS) and two of HPS and multiple organ dysfunction syndromes (MODS). In patients with stage I/II disease (Figure [1](#hon2637-fig-0001){ref-type="fig"}), the 1, 2, and 3‐year OS and PFS rates were 86.7%/85.2%, 79.3%/75.2%, and 62.9%/60.3%, respectively, for the DDGP + IMRT regimen; 82.0%/80.2%, 78.4%/76.5%, and 63.1%/60.5%, respectively, for the DDGP regimen; and 56.3%/52.1%, 41.2%/39.8%, and 38.1%/36.2%, respectively, for the SMILE regimen. The 1‐year OS and PFS rates for the AHSCT regimen were 38.3% and 35.2%, respectively. The 1‐year OS and PFS rates for the VIPD regimen were 78.9% and 76.3%, respectively. In patients with stage III/IV disease, the 1, 2, and 3‐year OS and PFS rates were 73.2%/72.1%, 43.9%/40.2%, and 32.7%/29.6%, respectively; for the SMILE regimen, 71.7%/69.9%, 38.7%/36.9%, and 28.5%/26.8%, respectively; for the DDGP + IMRT regimen; and 69.9%/64.3%, 36.3%/34.9%, and 25.6%/22.3%, respectively, for the DDGP regimen. The 1‐year OS and PFS rates for the AHSCT regimen were 66.5% and 65.1%, respectively. The 1‐year OS and PFS rates for the VIPD regimen were 51.3% and 49.2%, respectively.
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Besides, for the whole cohort, the 1, 2, and 3‐year OS and PFS rates were 79.2%/77.6%, 59.1%/56.1%, and 45.7%/43.6%, respectively, for the DDGP + IMRT regimen; 75.9%/72.3%, 57.4%/55.7%, and 44.3%/41.4%, respectively, for the DDGP regimen; and 64.7%/62.3%, 42.6%/40.1%, and 35.4%/32.9%, respectively, for the SMILE regimen. The 1‐year OS and PFS rates for the VIPD regimen were 65.1% and 62.8%, respectively. The 1‐year OS and PFS rates for the AHSCT regimen were 52.4% and 50.2%, respectively.

Our analysis shows that the DDGP + IMRT regimen results in significantly better outcomes in patients with ENKL. For stage I/II patients who cannot tolerate radiotherapy, the DDGP regimen is a better option, while for stage III/IV patients, the SMILE regimen is more effective.
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